Originally published by our sister publication Clinical Oncology News
By Ted Bosworth
In highly pretreated histone lysine N-methyltransferase 2A (KMT2A)-rearranged acute leukemia, which is associated with a very poor prognosis, a small molecule inhibitor of the menin–KMT2A interaction, revumenib (Syndax), provided impressive rates of response in a pivotal phase 2 trial.
For patients with this particular subtype of acute leukemia, the median overall survival (OS) following relapse after